Related Experiment Videos
To statin or to non-statin in coronary disease--considering absolute risk is the answer
1Cardiovascular Division, Department of Internal Medicine, University of Virginia, Charlottesville, VA 22908, USA. crembold@virginia.edu
Insights
For coronary artery disease (CAD), statins offer benefits, but non-statin therapies like niacin and gemfibrozil may provide greater risk reduction in certain patients. A Mediterranean diet also shows promise for cardiovascular health.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Preventive Cardiology
Background:
- Current coronary artery disease (CAD) guidelines emphasize statin therapy for LDL cholesterol lowering, irrespective of baseline levels.
- Recent trials demonstrate statistically significant relative risk reductions (RRR) in cardiovascular events with statins.
- Established non-statin anti-atherosclerotic treatments exist but are less emphasized in recent guidelines.
Purpose of the Study:
- To guide physicians in selecting optimal anti-atherosclerotic treatments based on individual patient benefit.
- To compare the efficacy of statin and non-statin therapies using absolute risk reduction (ARR) analysis.
- To evaluate treatment benefits across different CAD patient profiles, including stable and acute coronary syndrome (ACS) phases.
Main Methods:
- Analysis of clinical trial data focusing on absolute risk reduction (ARR) to account for baseline cardiovascular risk.
- Comparison of statin therapy versus non-statin agents (niacin, gemfibrozil) in patients with chronic CAD.
- Evaluation of treatment effects in the first year post-acute coronary syndrome (ACS) and in chronic CAD.
Main Results:
- Statin therapy showed significant benefit in stable CAD with high LDL cholesterol but diminishing returns at lower levels.
- Niacin or gemfibrozil provided comparable or greater ARR than statins in chronic CAD patients with lower LDL cholesterol.
- Mediterranean diet and statin therapy (targeting LDL ~80 mg/dL) demonstrated benefit in the first year post-ACS and in chronic CAD.
Conclusions:
- Absolute risk reduction (ARR) is crucial for personalized treatment decisions in CAD management.
- Non-statin therapies offer significant, potentially superior, benefits for specific patient groups with lower LDL cholesterol.
- Both statin and non-statin therapies, alongside lifestyle interventions like the Mediterranean diet, are vital for managing atherosclerosis.
Abstract:
The newest guidelines for treating people with coronary artery disease (CAD) suggest benefit from statin-induced LDL cholesterol lowering regardless of baseline LDL cholesterol level. These guidelines were based on recent clinical trials that showed statistically significant statin-induced relative risk reductions (RRR) in cardiovascular events. However, there are proven "non-statin" anti-atherosclerotic treatments. This analysis was designed to allow the physician to decide which patients benefit from the various anti-atherosclerotic treatments available. Analysis is presented as absolute risk reduction (ARR) because ARR takes baseline risk into account. There was a large benefit from statin therapy in stable CAD when LDL cholesterol levels were high. There were diminishing returns, despite statistically significance, with statin treatment of people with chronic CAD and lower LDL cholesterol levels. People with chronic CAD and lower LDL cholesterol levels had at least as much and possibly twice the ARR when treated with niacin or gemfibrozil as that would occur with statin treatment. For the first year after the acute coronary syndrome, risk was higher than in stable CAD, and trials showed a benefit especially with a Mediterranean diet and also with statin therapy that reduced LDL cholesterol levels to approximately 80 mg dl(-1). The Mediterranean diet was also beneficial in chronic CAD. These results suggest that both statin and non-statin therapy are important for reducing the sequelae of atherosclerosis.
Related Concept Videos
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Relative Risk
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Coronary Artery Disease V: Interprofessional Care